Biotech company Ophthotech Corporation has entered into an exclusive global license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania (Penn) to commercialize a treatment for a disease that causes blindness.
The licensed technology is an adeno-associated virus (AAV) gene therapy to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease characterized by progressive and severe loss of vision leading to blindness. Proof-of-concept studies of the therapy have shown promising results in a canine disease model, and Ophthotech plans to launch a Phase 1/2 clinical trial in early 2020.
Learn more about U of Florida and Penn Ink Licensing Deal for Gene Therapy to Treat Retinal Disease.
